NanoViricides Announces Successful Completion of Phase I Clinical Trial for NV-387

NanoViricides, Inc., a prominent developer of antiviral nanomedicines, has declared the successful completion of the Phase I Clinical Trial for NV-387. This initial phase was conducted under protocol KM-NVCoV2-001 and recently concluded in April 2024 in collaboration with Karveer Meditech, Pvt. Ltd., and PristynCR in India.

The trial, permitted by Indian regulators for both healthy and COVID-19 participants, faced a lack of COVID-19 cases, leading to completion solely with healthy volunteers. Despite this, the trial achieved its endpoints without any adverse effects reported across both single and multiple dose segments, evaluating the drug's safety at various dosages via oral syrups and gummies.

Following this phase, NanoViricides aims to proceed to Phase II discussions and trials, particularly analyzing NV-387's broad effectiveness against multiple viruses like RSV and smallpox/Mpox related viruses, showcased in prior lethal animal studies. This precedes their planned pre-IND submission for a Phase II trial focused on RSV infections in a diverse age group considering the high global need for RSV treatments.

The company envisions NV-387 as a comprehensive treatment for various viral infections, potentially simplifying antiviral treatments to a single drug regardless of the specific virus, akin to broad-spectrum antibiotics.